CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sep. 6, 2018--
Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical
company developing novel medicines to treat life-altering central
nervous system (CNS) disorders, today announced that the Company will
present at the Morgan Stanley 16th Annual Global Healthcare Conferenceon Wednesday, September 12, 2018 at 01:40 P.M. ET in New York, NY.
A live webcast of the presentation can be accessed on the investor page
of Sage's website at investor.sagerx.com. A replay of the webcast will
also be archived for up to 30 days on Sage's website following the
conference.
About Sage Therapeutics
Sage Therapeutics is a clinical-stage biopharmaceutical company
committed to developing novel medicines to transform the lives of
patients with life-altering CNS disorders. Sage's lead product
candidate, ZULRESSO™ (brexanolone injection), has completed Phase 3
clinical development for postpartum depression and a New Drug
Application is currently under review with the U.S. Food and Drug
Administration. Sage is developing a portfolio of novel product
candidates targeting critical CNS receptor systems, including SAGE-217,
which is in Phase 3 development in major depressive disorder and
postpartum depression. For more information, please visit www.sagerx.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180906005905/en/
Source: Sage Therapeutics
Sage Therapeutics
Investor Contact:
Paul Cox,
617-299-8377
paul.cox@sagerx.com
or
Media
Contact:
Jeff Boyle, 617-949-4256
jeff.boyle@sagerx.com